Commentary

In this issue of the Journal of Neuroscience in Rural Practice, Chaker *et al.*^[1] describe the case of an elderly patient presenting with diplopia, resulting from sixth nerve palsy, following acute infection of herpes zoster ophthalmicus (HZO). The authors describe the transient, self-limiting nature of cranial nerve (CN) VI palsy with favorable prognosis.

HZO occurs more commonly in patients over 50 years of age due to age-related decline in immunity. Cranial

nerve palsy following HZO has been reported with ocular-motor (cranial nerve (CN III), trochlear (CN IV) and abducens (CN VI) nerves most commonly affected.^[2] Other causes of CN palsies include intracranial space-occupying lesions, micro-vascular infarctions, trauma or inflammation. The most common cause of CN VI palsy in the elderly is micro-vascular ischemia associated with diseases such as diabetes mellitus and hypertension. Due to diverse causality, a comprehensive history should be obtained and a thorough ocular and cranial nerve

examination should be performed to direct the need for further investigations such as magnetic resonance imaging or angiogram (MRI or MRA), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and cerebrospinal fluid polymerase chain reaction (PCR), particularly in the absence of zosteriform rash.^[3]

Oral valacyclovir (1000 mg) or famciclovir (500 mg) three times daily for seven days are the recommended antiviral therapies for HZO, due to significant reductions in risk of developing post-herpetic neuralgia compared to oral acyclovir (800 mg five times daily for seven days).^[4] Adjunct corticosteroids have been reported to improve diplopia associated with CN palsy following HZO,^[3] although researchers are still unravelling the pathophysiology of this HZO complication. The addition of corticosteroids in patients with active infection should be carefully considered, with the aim to avoid potentiating existing infection. However, cranial nerve palsies associated with HZO are often reported approximately one week following HZO symptom onset and after antiviral therapy commencement, thereby decreasing this risk. Of interest, Nithyanandam *et al.*^[5] report a comparable HZO complication rate in HIV infected patients when antiviral therapy is instigated within 72 h.

Of note, CN palsies in HZO can sometimes present atypically. Czyz *et al.*^[6] reported a case of complete paralytic mydriasis as the only symptom of partial CN III involvement. While Babu *et al.*^[7] described a patient with CN III and VI involvement presenting with nodular scleritis and nummular keratouveitis. The importance of comprehensive slit lamp examination of the eye including dilated fundus examination, as well as cranial nerve assessment in all cases of HZO cannot be overemphasised.

Zoster vaccination aims to decrease the severity and duration of herpes zoster and minimize complications of infection. Tseng *et al.*^[8] conducted a large cohort study investigating zoster vaccine safety and reported no increased risk of Bell's palsy or Ramsey-Hunt syndrome following vaccination in patients over the age of 50. However, recurrent CN VI palsy has been reported in a child following vaccination against varicella, measles, mumps and rubella.^[9] Although the live attenuated zoster vaccine has been noted to be not as effective in patients

with reduced immune response, and is contraindicated in immunosuppressed patients, it is specifically these patients that require the most protection. Therefore, an efficacious-inactivated VZV vaccine is also needed to protect patients most at risk.^[10]

Elissa M. McDonald, Dipika V. Patel

Department of Ophthalmology, New Zealand National Eye Centre,
University of Auckland, New Zealand

Address for correspondence:

Dr. Elissa M. McDonald,
Department of Ophthalmology, University of Auckland,
Private Bag 92019, Auckland 1142, New Zealand.
Email: elissa_mcdonald@hotmail.com

References

1. Chaker N, Bouladi M, Chebil A, Jemmeli M, Mghaieth F, El Matri L. Herpes zoster ophthalmicus associated with abducens palsy. *J Neurosci Rural Prac* 2014;5:180-2.
2. Harthan JS, Borgman CJ. Herpes zoster ophthalmicus-induced oculomotor nerve palsy. *J Optom* 2013;6:60-5.
3. Pisapia R, Rianda A, Mariano A, Testa A, Galgani S, Vincenzi L, *et al.* Varicella zoster virus infection presenting as isolated diplopia: A case report. *BMC Infect Dis* 2013;13:138.
4. McDonald EM, de Kock J, Ram FS. Antivirals for management of herpes zoster including ophthalmicus: A systematic review of high-quality randomized controlled trials. *Antivir Ther* 2012;17:255-64.
5. Nithyanandam S, Joseph M, Stephen J. Ocular complications and loss of vision due to herpes zoster ophthalmicus in patients with HIV infection and a comparison with HIV-negative patients. *Int J STD AIDS* 2013;24:106-9.
6. Czyz CN, Bacon TS, Petrie TP, Justice JD, Cahill KV. Isolated, complete paralytic mydriasis secondary to herpes zoster ophthalmicus. *Pract Neurol* 2013;13:183-4.
7. Babu K, Kini R, Murthy KR. Unique presentation of 3rd and 6th cranial nerve palsies, nodular scleritis and nummular keratouveitis in an immunocompetent patient following an attack of herpes zoster ophthalmicus. *Ocul Immunol Inflamm* 2012;20:365-7.
8. Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E, *et al.* Safety of zoster vaccine in adults from a large managed-care cohort: A vaccine safety datalink study. *J Intern Med* 2012;271:510-20.
9. Cheng DR, Crawford NW, Hayman M, Buckley C, Buttery JP. Recurrent 6th nerve palsy in a child following different live attenuated vaccines: Case report. *BMC Infect Dis* 2012;12:105.
10. Doerr HW. Progress in VZV vaccination? Some concerns. *Med Microbiol Immunol* 2013;202:257-8.

Access this article online

Quick Response Code:

Website:
www.ruralneuropractice.com